Business Description
SpyGlass Pharma Inc
NAICS : 541714
SIC : 2836
ISIN : US8066051017
Total Employee Number:
65Description
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 156.19 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 39.41 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.9 | |||||
9-Day RSI | 53.42 | |||||
14-Day RSI | 52.26 | |||||
3-1 Month Momentum % | -23.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 38 | |||||
Quick Ratio | 38 | |||||
Cash Ratio | 37.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 0.25 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -123.53 | |||||
ROA % | -15.78 | |||||
ROIC % | -260.74 | |||||
ROC (Joel Greenblatt) % | -657.39 | |||||
ROCE % | -18.17 | |||||
Moat Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.75 | |||||
Price-to-Tangible-Book | 2.76 | |||||
EV-to-EBIT | -15.13 | |||||
EV-to-Forward-EBIT | -6.69 | |||||
EV-to-EBITDA | -15.41 | |||||
EV-to-FCF | -18.33 | |||||
| Price-to-Net-Current-Asset-Value | 2.82 | |||||
| Price-to-Net-Cash | 2.85 | |||||
Earnings Yield (Greenblatt) % | -6.61 | |||||
FCF Yield % | -3.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SGP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SpyGlass Pharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.083 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 52.26 | ||
| 14-Day ATR ($) | 1.737832 | ||
| 20-Day SMA ($) | 19.8875 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 17.06 - 32.44 | ||
| Shares Outstanding (Mil) | 33.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SpyGlass Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SpyGlass Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 137 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 46 days | ||
| General meeting for 2026 | 2026-07-16 | -- | ||
| First quarter earnings results for 2026 | 2026-05-14 | 23.82 (-1.85%) | ||
| Annual report for 2025 | 2026-03-26 | 25.22 (+6.68%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 25.22 (+6.68%) |
Show
Entries
SpyGlass Pharma Inc Frequently Asked Questions
What is SpyGlass Pharma Inc(SGP)'s stock price today?
The current price of SGP is $20.66. The 52 week high of SGP is $32.44 and 52 week low is $17.06.
When is next earnings date of SpyGlass Pharma Inc(SGP)?
The next earnings date of SpyGlass Pharma Inc(SGP) is 2026-08-31 Est..
Does SpyGlass Pharma Inc(SGP) pay dividends? If so, how much?
SpyGlass Pharma Inc(SGP) does not pay dividend.
Guru Commentaries on NAS:SGP
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on SpyGlass Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers